<DOC>
	<DOCNO>NCT00430807</DOCNO>
	<brief_summary>Cortico-dependence frequent giant cell arteritis patient , drug prove ability prevent corticodependence . Hydrocychloroquine well tolerate immunomodulatory drug may corticosteroid spar potential accord immuno-pharmacological clinical data . We design multcentric double blind versus placebo randomize controled trial ass corticosteroid spar effect hydroxychloroquine non complicate giant cell arteritis .</brief_summary>
	<brief_title>Hydroxychloroquine Giant Cell Arteritis</brief_title>
	<detailed_description />
	<mesh_term>Arteritis</mesh_term>
	<mesh_term>Giant Cell Arteritis</mesh_term>
	<mesh_term>Polymyalgia Rheumatica</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>giant celle arteritis least 3 ACR criterion include disgnostic temporal artery biopsy corticosteroid treatment since less 1 month age le 85 year sign informed consent amaurosis fugax , loss vision , acute lumb ischemia , angina pectoris myocardium infarctus , mesenteric ischemia vascular complication relate GCA low life expectancy ( &lt; 2 year ) corticosteroid treatment since 30 day whatever dosage primary corticosteroid resistance define persistant symptom despite prednisone 15 day previous psychiatric trouble induce corticosteroid hydroxychloroquine contraindicate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>giant cell arteritis ,</keyword>
	<keyword>hydroxychloroquine ,</keyword>
	<keyword>corticosteroid sparing ,</keyword>
	<keyword>corticodependence</keyword>
</DOC>